As we gear up to enter the second quarter of 2024, a retrospective analysis reveals a significant decrease in the number of novel drugs approved during the first quarter of this year.
The data indicates that only six novel drugs secured FDA nod in the first quarter of this year, compared to thirteen approvals during the same period last year.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com